What is HiberGene Diagnostics?
HiberGene Diagnostics is recognized as Ireland's premier ISO-certified entity specializing in the design, development, and manufacturing of advanced molecular diagnostics products. The company is actively disrupting traditional patient testing timelines by engineering solutions for rapid point-of-care and near-patient molecular diagnostics, alongside high-throughput capabilities. With a robust history of product innovation, HiberGene Diagnostics has assembled a world-class, multidisciplinary team adept at end-to-end design, development, manufacturing, and marketing of top-tier clinical molecular diagnostics solutions.
How much funding has HiberGene Diagnostics raised?
HiberGene Diagnostics has raised a total of $7.7M across 2 funding rounds:
Series A
$2.3M
Series B
$5.5M
Series A (2015): $2.3M with participation from Kernel Capital and Enterprise Ireland
Series B (2017): $5.5M led by Cantor Fitzgerald and Kernel Capital
Key Investors in HiberGene Diagnostics
Kernel Capital
Kernel Capital is a venture capital and private equity firm that specializes in investing in growth stage and early stage companies. With a strong focus on providing not just capital but also strategic guidance, they support their portfolio companies in scaling and achieving successful exits.
Enterprise Ireland
Enterprise Ireland, headquartered in Dublin, Leinster and established in 1998, is a government agency responsible for the development and growth of Irish businesses in the manufacturing and internationally traded services industries.
Cantor Fitzgerald
Founded in 1945 and headquartered in Cantor Fitzgerald, a financial services firm, provides services for institutional debt, equity sales, trading, investment banking and real estate private equity.
What's next for HiberGene Diagnostics?
The substantial enterprise-level funding HiberGene Diagnostics has attracted, particularly the recent strategic investment, positions the company for accelerated scaling and market penetration. This capital infusion is expected to fuel further research and development, enhance manufacturing capacity, and expand its commercial reach. The company's focus on rapid, point-of-care molecular diagnostics aligns with growing global healthcare demands for faster and more accessible testing, suggesting a strong future outlook for continued growth and innovation in the diagnostics sector.
See full HiberGene Diagnostics company page
